文献速递炎症性肠病

手术中注射含富血小板血浆的基质血管成分在难治性肛周瘘管型克罗恩病中可行且安全:一项先导研究

Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-26

这项先导研究纳入25例难治性肛周瘘管型克罗恩病患者,在手术中行瘘管刮除、注射自体基质血管成分(SVF)联合富血小板血浆(PRP)并闭合内口。主要终点为12个月安全性,未在脂肪采集部位发现不良事件;术后MRI(n=24)显示9例(37.5%)达到完全影像学愈合,12个月时17例(68%)部分临床缓解、10例(40%)完全临床闭合。作者认为该治疗可行且安全。

要点

  • 25例难治性肛周瘘管型克罗恩病患者接受手术中SVF联合PRP注射,脂肪采集部位未发生不良事件。
  • 2例(8%)患者再入院,6例(24%)接受非计划再次干预。
  • 术后MRI(n=24)显示9例(37.5%)完全影像学愈合;12个月时部分临床缓解68%(17/25)、完全临床闭合40%(10/25)。

核心结论

  • 作者认为,自体SVF联合PRP注射在难治性肛周瘘管型克罗恩病患者中可行且安全;超过三分之一患者观察到早期完全影像学愈合,三分之二患者在12个月时出现临床缓解。

研究设计与样本

  • 先导研究,纳入25例年龄≥18岁的肛周瘘管型克罗恩病患者,中位年龄35岁(IQR 25-40),14例(56%)为女性,中位克罗恩病病程4年(IQR 2-8)。
  • 患者接受瘘管刮除、SVF联合PRP注射及内口闭合;主要终点为12个月安全性,次要终点包括3个月完全影像学愈合(MRI上无含液瘘管)以及3个月和12个月的部分与完全临床缓解。

主要发现

  • 脂肪采集部位未发生不良事件;2例(8%)患者再入院,6例(24%)接受非计划再次干预。
  • 术后MRI(n=24)显示9例(37.5%)达到完全影像学愈合。
  • 部分临床缓解在3个月时为48%(12/25),在12个月时为68%(17/25)。
  • 完全临床闭合在3个月时为5例(20%),在12个月时为10例(40%)。
  • 24例(95%)患者既往曾接受瘘管手术。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An unmet need remains for improved management in perianal fistulising Crohn's disease (pCD). Recently, local administration of adipose-derived cells has shown promising results. AIMS: To assess the safety and feasibility of injection of stromal vascular fraction (SVF) with platelet-rich plasma (PRP) in patients with pCD. METHODS: Patients ≥ 18 years with pCD were included and underwent fistula curettage, SVF with PRP injection, and closure of the internal opening. The primary endpoint was safety at 12 months. The secondary outcomes were complete radiological healing at 3 months (absence of fluid-containing tracts on MRI) and partial and complete clinical response at 3 and 12 months (closure of ≥1, respectively, all treated external opening(s)). RESULTS: Twenty-five patients were included (35 [IQR 25-40] years; 14 [56%] female); median CD duration 4 [IQR 2-8] years. Twenty-four (95%) patients had previously undergone fistula surgery. No adverse events were encountered at lipoharvesting sites. Two (8%) patients were readmitted to hospital and six (24%) underwent unplanned re-interventions. Post-operative MRI (n = 24) showed complete radiological healing in nine (37.5%) patients. Partial clinical response was present in 48% (12/25) at 3 months and in 68% (17/25) at 12 months, and complete clinical closure in five (20%) patients at 3 months and in 10 (40%) patients at 12 months. CONCLUSION: Injection with autologous SVF with PRP is feasible and safe in patients with treatment-refractory pCD. Early complete radiological healing was observed in more than one-third of patients, and clinical response in two-thirds of patients at 12 months.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Arkenbosch JHC, van Ruler O, Dwarkasing RS, et al. Stromal vascular fraction with platelet-rich plasma injection during surgery is feasible and safe in treatment-refractory perianal fistulising Crohn's disease: A pilot study. Aliment Pharmacol Ther. 2022. PMID: 36571818. doi:10.1111/apt.17347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。